Pirfenidone attenuates bladder fibrosis and mitigates deterioration of bladder function in a rat model of partial bladder outlet obstruction

Duan,Liu  Jian; Qi,Jun; Huang,Tao; Gu,Xin; Xu,Ding; Kong,Xiang  Jie; Qian,Xiao  Qiang

doi:10.3892/mmr.2015.3814

Pirfenidone attenuates bladder fibrosis and mitigates deterioration of bladder function in a rat model of partial bladder outlet obstruction

Authors:
- Liu Jian Duan
- Jun Qi
- Tao Huang
- Xin Gu
- Ding Xu
- Xiang Jie Kong
- Xiao Qiang Qian
View Affiliations

Affiliations: Department of Urology, Xin Hua Hospital Afﬁliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, P.R. China
Published online on: May 21, 2015 https://doi.org/10.3892/mmr.2015.3814
Pages: 3639-3647

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To investigate the effects of pirfenidone (PFD) on the attenuation of bladder remodeling, and the associated functional changes caused by partial bladder outlet obstruction (pBOO), the present study performed surgery on adult male Sprague‑Dawley rats produce a model of pBOO. The rats in the pBOO group were administered a placebo and, in the CMC group, PFD mixed with the placebo was administered orally at 500 mg/kg body weight each day for 5 weeks, from 1 week after surgery. The rat bladders were harvested for biochemical analysis following cystometry at the end of the 6 week period. The histopathology was determined using Masson's trichrome staining. The mRNA and protein levels of pro‑fibrotic growth factors and extracellular matrix subtypes were assessed. pBOO debilitated bladder function and caused the parameters from cystometry to increase significantly compared with those in the control group (P<0.05), which were mitigated significantly following PFD treatment (P<0.05). In terms of the histology, the rats in the pBOO group exhibited significant increases in bladder weight, muscle hypertrophy and deposition of collagens, which were suppressed by PFD treatment (P<0.05). Based on the biochemical analysis, significant increases in the mRNA levels of collagen subtypes and growth factors, and protein levels of profibrotic growth factors and α‑smooth muscle actin in the bladders of rats in the pBOO group were reduced following PFD treatment. PFD prevented bladder remodeling and attenuated bladder fibrosis and, therefore, mitigated the deterioration of bladder function during the initial stage of pBOO.

View Figures

View References

1	Metcalfe PD, Wang J, Jiao H, et al: Bladder outlet obstruction: progression from inflammation to fibrosis. Bju Int. 106:1686–1694. 2010. View Article : Google Scholar : PubMed/NCBI
2	Baskin LS, Sutherland RS, Thomson AA, et al: Growth factors and receptors in bladder development and obstruction. Lab Invest. 75:157–166. 1996.PubMed/NCBI
3	Kim JC, Yoon JY, Seo SI, et al: Effects of partial bladder outlet obstruction and its relief on types I and III collagen and detrusor contractility in the rat. Neurourol Urodyn. 19:29–42. 2000. View Article : Google Scholar
4	Kaplan EP, Richier JC, Howard PS, et al: Type III collagen messenger RNA is modulated in non-compliant human bladder tissue. J Urol. 157:2366–2369. 1997. View Article : Google Scholar : PubMed/NCBI
5	Wick G, Backovic A, Rabensteiner E, et al: The immunology of fibrosis: innate and adaptive responses. Trends Immunol. 31:110–119. 2010. View Article : Google Scholar : PubMed/NCBI
6	Iyer SN, Margolin SB, Hyde DM and Giri SN: Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res. 24:119–132. 1998. View Article : Google Scholar : PubMed/NCBI
7	Kehrer JP and Margolin SB: Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol Lett. 90:125–132. 1997. View Article : Google Scholar : PubMed/NCBI
8	Azuma A, Nukiwa T, Tsuboi E, et al: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 171:1040–1047. 2005. View Article : Google Scholar : PubMed/NCBI
9	Navarro-Partida J, Martinez-Rizo Ab, Gonzalez-Cuevas J, Arrevillaga-Boni G, Ortiz-Navarrete V and Armaendariz-Borunda J: Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis. Eur J Pharmacol. 678:71–77. 2012. View Article : Google Scholar : PubMed/NCBI
10	García L, Hernández I, Sandoval A, et al: Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol. 37:797–805. 2002. View Article : Google Scholar : PubMed/NCBI
11	Chen JF, Ni HF, Pan MM, et al: Pirfenidone inhibits macrophage infiltration in 5/6 nephrectomized rats. Am J Physiol Renal Physiol. 304:F676–F685. 2013. View Article : Google Scholar
12	Shi Q, Liu X, Bai Y, et al: In vitro effects of pirfenidone on cardiac fibroblasts: Proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS One. 6:e281342011. View Article : Google Scholar : PubMed/NCBI
13	Armaendariz-Borunda J, Lyra-Gonzalez I, Medina-Preciado D, et al: A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. Ann Plast Surg. 68:22–28. 2012. View Article : Google Scholar
14	Zhao XY, Zeng X, Li XM, et al: Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells. Clin Exp Pharmacol Physiol. 36:963–968. 2009. View Article : Google Scholar : PubMed/NCBI
15	Iyer SN, Gurujeyalakshmi G and Giri SN: Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 291:367–373. 1999.PubMed/NCBI
16	Liu F, Yao L, Yuan J, et al: Protective effects of inosine on urinary bladder function in rats with partial bladder outlet obstruction. Urology. 73:1417–1422. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kim JW, Jang HA, Bae JH and Lee JG: Effects of coenzyme Q10 on bladder dysfunction induced by chronic bladder ischemia in a rat model. J Urol. 189:2371–2376. 2013. View Article : Google Scholar : PubMed/NCBI
18	Oku H, Shimizu T, Kawabata T, et al: Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 590:400–408. 2008. View Article : Google Scholar : PubMed/NCBI
19	Parekh A, Long RA, Chancellor MB and Sacks MS: Assessing the effects of transforming growth factor-beta1 on bladder smooth muscle cell phenotype. II Modulation of collagen organization. J Urol. 182:1216–1221. 2009. View Article : Google Scholar : PubMed/NCBI
20	Cortivo R, Pagano F, Passerini G, et al: Elastin and collagen in the normal and obstructed urinary bladder. Br J Urol. 53:134–137. 1981. View Article : Google Scholar : PubMed/NCBI
21	Ewalt DH, Howard PS, Blyth B, et al: Is lamina propria matrix responsible for normal bladder compliance? J Urol. 148:544–549. 1992.PubMed/NCBI
22	Djavan B, Lin V, Kaplan EP, et al: Decreased elastin gene expression in noncompliant human bladder tissue: a competitive reverse transcriptase-polymerase chain reaction analysis. J Urol. 160:1658–1662. 1998. View Article : Google Scholar : PubMed/NCBI
23	Toosi KK, Nagatomi J, Chancellor MB and Sacks MS: The effects of long-term spinal cord injury on mechanical properties of the rat urinary bladder. Ann Biomed Eng. 36:1470–1480. 2008. View Article : Google Scholar : PubMed/NCBI
24	Bai J, Liu XS, Xu YJ, Zhang ZX, Xie M and Ni W: Extracellular signal-regulated kinase activation in airway smooth muscle cell proliferation in chronic asthmatic rats. Sheng Li Xue Bao. 59:311–318. 2007.PubMed/NCBI
25	Schultz K, Murthy V, Tatro JB and Beasley D: Endogenous interleukin-1 alpha promotes a proliferative and proinflammatory phenotype in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 292:H2927–H2934. 2007. View Article : Google Scholar : PubMed/NCBI
26	Runyan CE, Poncelet AC and Schnaper HW: TGF-beta receptor-binding proteins: complex interactions. Cell Signal. 18:2077–2088. 2006. View Article : Google Scholar : PubMed/NCBI
27	Leask A and Abraham DJ: TGF-beta signaling and the fibrotic response. FASEB J. 18:816–827. 2004. View Article : Google Scholar : PubMed/NCBI
28	Howard PS, Kucich U, Coplen DE and He Y: Transforming growth factor-beta1-induced hypertrophy and matrix expression in human bladder smooth muscle cells. Urology. 66:1349–1353. 2005. View Article : Google Scholar : PubMed/NCBI
29	Barendrecht MM, Mulders AC, van der Poel H, et al: Role of transforming growth factor beta in rat bladder smooth muscle cell proliferation. J Pharmacol Exp Ther. 322:117–122. 2007. View Article : Google Scholar : PubMed/NCBI
30	Schaefer CJ, Ruhrmund DW, Pan L, et al: Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 20:85–97. 2011. View Article : Google Scholar : PubMed/NCBI
31	Salazar-Montes A, Ruiz-Corro L, López-Reyes A, et al: Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur J Pharmacol. 595:69–77. 2008. View Article : Google Scholar : PubMed/NCBI
32	Oku H, Nakazato H, Horikawa T, et al: Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol. 446:167–176. 2002. View Article : Google Scholar : PubMed/NCBI
33	Tada S, Nakamuta M, Enjoji M, et al: Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin Exp Pharmacol Physiol. 28:522–527. 2001. View Article : Google Scholar : PubMed/NCBI
34	Simone NL, Soule BP, Gerber L, et al: Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study. Radiat Oncol. 2:192007. View Article : Google Scholar : PubMed/NCBI
35	Walker JE, Giri SN and Margolin SB: A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Mult Scler. 11:149–158. 2005. View Article : Google Scholar : PubMed/NCBI
36	Alcántar-Díaz BE, Gómez-Meda BC, Zúñiga-González GM, et al: Genotoxic evaluation of pirfenidone using erythrocyte rodent micronucleus assay. Food Chem Toxicol. 50:2760–2765. 2012. View Article : Google Scholar : PubMed/NCBI
37	Pandita RK, Fujiwara M, Alm P and Andersson KE: Cystometric evaluation of bladder function in non-anesthetized mice with and without bladder outlet obstruction. J Urol. 164:1385–1389. 2000. View Article : Google Scholar : PubMed/NCBI